ATE370955T1 - N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden. - Google Patents
N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden.Info
- Publication number
- ATE370955T1 ATE370955T1 AT04757294T AT04757294T ATE370955T1 AT E370955 T1 ATE370955 T1 AT E370955T1 AT 04757294 T AT04757294 T AT 04757294T AT 04757294 T AT04757294 T AT 04757294T AT E370955 T1 ATE370955 T1 AT E370955T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfonylheterocyclopyrrolylalkylamin
- hydroxytryptamine
- ligands
- compounds
- receptor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49162203P | 2003-07-31 | 2003-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370955T1 true ATE370955T1 (de) | 2007-09-15 |
Family
ID=34115532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04757294T ATE370955T1 (de) | 2003-07-31 | 2004-07-23 | N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7041695B2 (de) |
| EP (1) | EP1648904B1 (de) |
| JP (1) | JP2007500701A (de) |
| CN (1) | CN100443487C (de) |
| AT (1) | ATE370955T1 (de) |
| AU (1) | AU2004261606A1 (de) |
| BR (1) | BRPI0413158A (de) |
| CA (1) | CA2532382A1 (de) |
| DE (1) | DE602004008474T2 (de) |
| DK (1) | DK1648904T3 (de) |
| ES (1) | ES2290740T3 (de) |
| MX (1) | MXPA06000957A (de) |
| PL (1) | PL1648904T3 (de) |
| WO (1) | WO2005012311A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2532382A1 (en) * | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
| GB0403781D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical compounds |
| US7314875B2 (en) | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| US7495111B2 (en) * | 2005-06-17 | 2009-02-24 | Wyeth | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists |
| TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
| TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| CL2007003410A1 (es) * | 2006-11-28 | 2008-04-11 | Wyeth Corp | Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast |
| CL2008000119A1 (es) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| EP2053052A1 (de) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Verfahren zur Herstellung von 6-substituiertem Imidazo[2,1-b]thiazol-5-sulfonylhalogenid |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| MX2019012728A (es) | 2017-04-24 | 2020-01-23 | Bayer Ag | Derivados de heterociclos biciclicos fusionados como plaguicidas. |
| CN120289484A (zh) * | 2025-04-16 | 2025-07-11 | 聊城大学 | 一种吡咯烷酮并二氢异噁唑类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537974A1 (fr) * | 1982-12-16 | 1984-06-22 | Adir | Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| DE69930308T2 (de) * | 1998-12-11 | 2006-11-30 | Virginia Commonwealth University | Selektive 5-ht 6-rezeptor-liganden |
| GB0016454D0 (en) * | 2000-07-04 | 2000-08-23 | Hoffmann La Roche | Thienopyrrolidinones |
| DE10063992A1 (de) | 2000-12-21 | 2002-07-04 | Max Planck Gesellschaft | Tryptophan-Analoga in Proteinen, Peptiden und peptidischen Leitstrukturen |
| MXPA03005433A (es) * | 2000-12-22 | 2003-09-10 | Wyeth Corp | Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6. |
| US6730694B1 (en) * | 2001-07-20 | 2004-05-04 | Eli Lilly And Company | sPLA2 inhibitors |
| AU2002357270B2 (en) * | 2001-12-20 | 2007-06-14 | Wyeth | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| ES2298545T3 (es) * | 2002-08-21 | 2008-05-16 | Astrazeneca Ab | Compuestos de tieno-pirrol como antagonistas de la hormona liberadora de gonadotropina. |
| TW200407127A (en) | 2002-08-21 | 2004-05-16 | Astrazeneca Ab | Chemical compounds |
| CA2532382A1 (en) * | 2003-07-31 | 2005-02-10 | Wyeth | N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
-
2004
- 2004-07-23 CA CA002532382A patent/CA2532382A1/en not_active Abandoned
- 2004-07-23 JP JP2006521964A patent/JP2007500701A/ja not_active Withdrawn
- 2004-07-23 DK DK04757294T patent/DK1648904T3/da active
- 2004-07-23 BR BRPI0413158-4A patent/BRPI0413158A/pt not_active IP Right Cessation
- 2004-07-23 WO PCT/US2004/023993 patent/WO2005012311A1/en not_active Ceased
- 2004-07-23 AT AT04757294T patent/ATE370955T1/de not_active IP Right Cessation
- 2004-07-23 EP EP04757294A patent/EP1648904B1/de not_active Expired - Lifetime
- 2004-07-23 PL PL04757294T patent/PL1648904T3/pl unknown
- 2004-07-23 CN CNB2004800210108A patent/CN100443487C/zh not_active Expired - Fee Related
- 2004-07-23 DE DE602004008474T patent/DE602004008474T2/de not_active Expired - Fee Related
- 2004-07-23 AU AU2004261606A patent/AU2004261606A1/en not_active Withdrawn
- 2004-07-23 ES ES04757294T patent/ES2290740T3/es not_active Expired - Lifetime
- 2004-07-23 MX MXPA06000957A patent/MXPA06000957A/es active IP Right Grant
- 2004-07-30 US US10/909,092 patent/US7041695B2/en not_active Expired - Fee Related
-
2006
- 2006-02-01 US US11/344,765 patent/US7220756B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005012311A1 (en) | 2005-02-10 |
| CN1826346A (zh) | 2006-08-30 |
| BRPI0413158A (pt) | 2006-10-03 |
| DE602004008474T2 (de) | 2008-05-15 |
| US20060160878A1 (en) | 2006-07-20 |
| PL1648904T3 (pl) | 2008-01-31 |
| AU2004261606A1 (en) | 2005-02-10 |
| US7041695B2 (en) | 2006-05-09 |
| MXPA06000957A (es) | 2006-03-30 |
| JP2007500701A (ja) | 2007-01-18 |
| US7220756B2 (en) | 2007-05-22 |
| DK1648904T3 (da) | 2007-10-22 |
| EP1648904B1 (de) | 2007-08-22 |
| US20050038088A1 (en) | 2005-02-17 |
| DE602004008474D1 (de) | 2007-10-04 |
| CN100443487C (zh) | 2008-12-17 |
| ES2290740T3 (es) | 2008-02-16 |
| CA2532382A1 (en) | 2005-02-10 |
| EP1648904A1 (de) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20070606L (no) | Inhibitorer av IAP | |
| ATE473975T1 (de) | Chemische verbindungen | |
| DE602006001515D1 (de) | Chemische verbindungen | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| MXPA04005886A (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6. | |
| EA200701467A1 (ru) | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) | |
| NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
| CY1108738T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου | |
| BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| MXPA05008438A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. | |
| ATE370955T1 (de) | N-sulfonylheterocyclopyrrolylalkylamin verbindungen als 5-hydroxytryptamin-6 liganden. | |
| EA200600971A1 (ru) | Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона | |
| MXPA06000701A (es) | Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6. | |
| MXPA04003087A (es) | Derivados de cromano como ligados de 5-hidroxitriptamina-6. | |
| EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| NO20080937L (no) | Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander | |
| ATE370147T1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
| BRPI0416371A (pt) | composto de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligantes de 5-hidroxitriptamina-6 | |
| MXPA06000700A (es) | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. | |
| ATE346040T1 (de) | Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |